Document is current
Any future updates will be listed below
-
Authors
Herwerth, Marina https://orcid.org/0000-0001-5125-4594
Wyss, Matthias T. https://orcid.org/0000-0002-2037-3424
Schmid, Nicola B.
Lasne, Anna https://orcid.org/0009-0006-7105-0226
Condrau, Jacqueline
Ravotto, Luca https://orcid.org/0000-0002-0431-9866
Mateos Melero, José María https://orcid.org/0000-0002-3675-6198
Kaech, Andres https://orcid.org/0000-0002-7035-9858
Bredell, Gustav
Thomas, Carolina https://orcid.org/0000-0002-7386-1181
Kim, Rachel https://orcid.org/0000-0001-6361-6206
Kukanja, Petra
Korobeynyk, Vladyslav L.
Stadelmann, Christine
Misgeld, Thomas https://orcid.org/0000-0001-9875-6794
Bennett, Jeffrey L.
Jessberger, Sebastian https://orcid.org/0000-0002-0056-8275
Saab, Aiman S. https://orcid.org/0000-0003-3886-8369
Liddelow, Shane A. https://orcid.org/0000-0002-0840-1437
Weber, Bruno https://orcid.org/0000-0002-9089-0689
- License Information
-
More Information
Article History
Received: 21 October 2025
Accepted: 29 May 2026
First Online: 23 July 2026
Ethics
Competing interests: M.H. served on scientific advisory boards of Biogen, Merck Serono, Alexion and Horizon Therapeutics (Amgen); has received speaker’s honoraria from Biogen and Neuraxpharm; and has received travel funding from Roche. J.L.B. reports personal fees from AbbVie, Alexion, Antigenomycs, BeiGene, Chugai, Clene Nanomedicine, EMD Serono, Genentech, Genzyme, Horizon Therapeutics, Mitsubishi Tanabe Pharma, MedImmune/Viela Bio, Novartis, Reistone Biopharma, Roche and TG Therapeutics for consultative work and service on scientific advisory boards; grants from Novartis, Mallinckrodt and Alexion; and a patent for aquaporumab. C.S. served on advisory boards of Roche and Novartis and received speaker’s honoraria from Novartis, Alexion, Merck Serono and BMS. T.M. received speaker honoraria from Novartis and Roche. The other authors declare no competing interests.
